Cholinesterase Inhibitors

Cholinesterase inhibitors are a class of anti-dementia drugs commonly used to treat Alzheimer’s disease. As the name implies, these drugs work by blocking the enzyme (acetylcholinesterase) that breaks down the neurotransmitter acetylcholine. Acetylcholine is important in regulating memory, cognitive function, and alertness in the brain, so blocking its breakdown can help to improve these functions in people with Alzheimer’s disease. The two most commonly prescribed cholinesterase inhibitors are donepezil and rivastigmine. Donepezil is given once a day in tablet form and works by blocking the enzyme action that breaks down acetylcholine. Rivastigmine is a form of gel with a time release mechanism that delivers the drug over a sustained period and works similarly. Cholinesterase inhibitors improve the levels of acetylcholine in the brain, which in turn helps the patient to better remember things, think more clearly, and stay alert. Because these drugs can slow down the progression of Alzheimer’s disease, they are usually taken for long periods of time, even if the patient has not experienced any noticeable improvement. The most common side effects of cholinesterase inhibitors are nausea, vomiting, and diarrhea. Other potential side effects include weight loss, increased sensitivity to sunlight, involuntary muscle jerking (myoclonus), and headaches. People taking these drugs may also be more prone to seizures. Cholinesterase inhibitors are considered a first-line therapy for Alzheimer’s disease, as they have been proven to slow the progression of the disease over time. While they cannot change the underlying causes of the disease or reverse any of the damage that has already occurred, they can be an important part of a comprehensive treatment plan for managing the progression of Alzheimer’s disease.